| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 - |
| 20 Aug 2026 | SCHEDULE 13G |
| 20 Aug 2026 |
Form 4: Tousignant Jennifer, Chief Legal Officer
Sold 14,212 shares ($348K) · Received 10,000 shares by exercise or conversion ($144K) |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Tripuraneni Radhika, Chief Medical Officer
Received 40,000 shares by exercise or conversion ($528K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of |
| 02 Jul 2026 |
Form 4: Cain Christopher W., Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Ajer Jeffrey Robert, Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Moses Jennifer K., Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Gheuens Sarah, Director
Granted 32,341 Stock Option (Right to Buy) |
Loading...